Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Mar 28, 2002
app pub date -
Aug 6, 2001
filing date -
Aug 7, 2000
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The present invention relates to novel tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidine compounds that are antagonists of alpha V (.alpha.v) integrins, for example .alpha..sub.v.beta..sub.3 and .alpha..sub.v.beta..sub.5 integrins, their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. The compounds may be used in the treatment of pathological conditions mediated by .alpha..sub.v.beta..sub.3 and .alpha..sub.v.beta..sub.5 integrins, including conditions such as tumor growth, metastasis, restenosis, osteoporosis, inflammation, macular degeneration, diabetic retinopathy, and rheumatoid arthritis. The compounds have the general formula: 1 where R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7R.sup.8, R.sup.9, R.sup.10, m and n are defined herein.
First Claim
Other Claims data not available